The orally bio-available small-molecule XPO1 inhibitors called selective inhibitor of nuclear export (SINE) compounds, have proven anti-cancer activity in hematological and solid cancers, while sparing normal cells and showing limited off-target complications [7, 8]. The gene discussed is XPO1; the disease is cancer.